Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chazhu Xiaozhi Decoction for Non-alcoholic Fatty Liver Disease
NCT06442137Phase 2Completed
- Sponsor
- Shanghai Municipal Hospital of Traditional Chinese Medicine
- Start
- Jul 2024
- Primary completion
- Nov 2024
- Modality
- HM (Herbal Medicine), NPI (Non-Pharmacological Intervention)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Chazhu Xiaozhi decoction in non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Shanghai Municipal Hospital of Traditional Chinese Medicine. Primary endpoints: Controlled Attenuation Parameter at 8 weeks and Traditional Chinese Medicine Syndrome Scale at 8 weeks. Started Jul 2024; status: completed.
02
Drugs
Chazhu Xiaozhi decoction
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT06442137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06442137.